The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of weekly oral docetaxel (ModraDoc001) plus ritonavir in patients with advanced solid tumors.
Serena Marchetti
No relevant relationships to disclose
Frederik Stuurman
No relevant relationships to disclose
Stijn Koolen
No relevant relationships to disclose
Johannes Moes
No relevant relationships to disclose
Jeroen Hendrikx
No relevant relationships to disclose
Bas Thijssen
No relevant relationships to disclose
Alwin D.R. Huitema
No relevant relationships to disclose
Bastiaan Nuijen
No relevant relationships to disclose
Hilde Rosing
No relevant relationships to disclose
Marianne Keessen
No relevant relationships to disclose
Emile E. Voest
No relevant relationships to disclose
M. Mergui-Roelvink
No relevant relationships to disclose
Jos H. Beijnen
No relevant relationships to disclose
Jan H. M. Schellens
No relevant relationships to disclose